FDA warned gorillahealing.com for selling unapproved, misbranded semaglutide and tirzepatide drugs to U.S. consumers online.
What happened
FDA reviewed the website www.gorillahealing.com (no inspection was conducted) and found it offering semaglutide and tirzepatide products for sale to U.S. consumers. Neither product has an FDA-approved application, and the site gives no instructions on how to prepare or dose the products, which the letter says appear to be intended for injection. FDA also said the labeling lacks adequate directions for use, making the drugs misbranded.
What FDA found
The website sells semaglutide and tirzepatide that FDA has never approved, which is illegal for a new drug.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The product labeling does not give adequate directions so that a layperson could use the drugs safely.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5Because the drugs are not approved, they do not qualify for the exemption from direction-for-use labeling.
21 CFR 201.115(a)Offering these drugs for sale to U.S. consumers puts misbranded drugs into interstate commerce.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks the company to stop offering unapproved and misbranded drugs for sale to U.S. consumers, and to reply in writing within 15 working days describing the specific steps taken to fix the violations and prevent them from recurring.
Who should pay attention
- online sellers of GLP-1 or peptide products
- telehealth and weight-loss clinics that refer patients to such sites
- consumers buying semaglutide or tirzepatide outside a pharmacy
This is a summary. Read the original letter on fda.gov.